Targeting a protein to reduce lung injury caused by viral infections.
Official title: Inducible HMGB1 antagonist for viral-induced acute lung injury.
Funded at Sigmovir Biosystems, INC. · NIH-11163178 · Data updated 2026-11-12
This study is looking at a new way to help people with lung injuries and breathing problems caused by viral infections, like COVID-19, by blocking a protein that makes inflammation worse, with the hope of improving their lung function.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sigmovir Biosystems, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | August 16, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $62,894 |
| NIH project number | 3R41HL167254-02S1 |
| Project ID | NIH-11163178 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing severe respiratory distress or acute lung injury due to viral infections, particularly those hospitalized with COVID-19 or influenza.
✕Less likely to help
Patients with lung injuries not caused by viral infections or those with chronic lung diseases may not benefit from this research.
What this research studies
This research investigates a potential treatment for acute lung injury and acute respiratory distress syndrome (ARDS) caused by viral infections, including the novel coronavirus. The approach focuses on blocking a specific protein, High Mobility Group Box 1 (HMGB1), which is involved in the inflammatory response that worsens lung injury. By using antagonists that inhibit this protein and the associated signaling pathways, the research aims to reduce inflammation and improve lung function in affected patients. The study utilizes preclinical models to test the effectiveness of these treatments before considering human applications.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve outcomes for patients suffering from severe lung injuries due to viral infections.
How similar studies have gone: Previous research has shown promise in targeting similar pathways to reduce lung injury, indicating that this approach may be effective.
Where this research is happening
-
Sigmovir Biosystems, INC.
Rockville, United States Active
Researchers
- Principal investigator: Blanco, Jorge C — Sigmovir Biosystems, INC.
- Study coordinator: Blanco, Jorge C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.